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Common variable immunodeficiency (CVID) and other late-onsetimmunodeficiencies often co-manifest with autoimmunity andlymphoproliferation. The pathogenesis of most cases is elusive, as
only a minor subset harbors known monogenic germline causes. The
involvement of both B and T cells is, however, implicated. To study
whether somatic mutations in CD4+ and CD8+ T cells associate with
immunodeficiency, we recruited 17 patients and 21 healthy controls. Eight
patients had late-onset CVID and nine patients other immunodeficiency
and/or severe autoimmunity. In total, autoimmunity occurred in 94% and
lymphoproliferation in 65%. We performed deep sequencing of 2,533
immune-associated genes from CD4+ and CD8+ cells. Deep T-cell receptor
b-sequencing was used to characterize CD4+ and CD8+ T-cell receptor
repertoires. The prevalence of somatic mutations was 65% in all immun-
odeficiency patients, 75% in CVID, and 48% in controls. Clonal
hematopoiesis-associated variants in both CD4+and CD8+ cells occurred in
24% of immunodeficiency patients. Results demonstrated mutations in
known tumor suppressors, oncogenes, and genes that are critical for
immune- and proliferative functions, such as STAT5B (2 patients), C5AR1
(2 patients), KRAS (one patient), and NOD2 (one patient). Additionally, as
a marker of T-cell receptor repertoire perturbation, CVID patients harbored
increased frequencies of clones with identical complementarity determin-
ing region 3 sequences despite unique nucleotide sequences when com-
pared to controls. In conclusion, somatic mutations in genes implicated for
autoimmunity and lymphoproliferation are common in CD4+ and CD8+
cells of patients with immunodeficiency. They may contribute to immune
dysregulation in a subset of immunodeficiency patients.  
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ABSTRACT
Introduction
Immunodeficiencies often manifest with autoimmune disease, as shown in the
most common primary immunodeficiency in the adult population: common vari-
able immunodeficiency (CVID).1 Although the main manifestations of CVID are
recurrent infections and low levels of plasma immunoglobulins, patients often
present with immune-mediated blood-cell cytopenias, enteropathy, arthritis, lym-
phoproliferation, and/or granulomatous disease.1 Currently known monogenic
causes  account for 2-10% of CVID cases.2 In the absence of disease-associated
germline variants, the etiology of CVID and other
delayed-onset immunodeficiency remains largely elusive.
Although a B-cell defect apparently causes hypogamma-
globulinemia, T-cell abnormalities also occur in CVID
patients. Decreased levels of regulatory T cells and naïve
CD4+ T cells, an increase in CD8+ expansion, disturbed
cytokine secretion, and large granular lymphocyte expan-
sions have all been described.1,3,4 Altered immune home-
ostasis may promote both immunodeficiency and infec-
tions. In CVID, the prevalence of autoimmune disease is
30%,1,3,5 lymphoproliferation 50%,3 and patients also have
an increased risk for malignant diseases. The standardized
incidence ratio for lymphomas and stomach cancer is 
10-12.1,6 
Somatic mutations play a key role in malignant transfor-
mation, while recent discoveries have highlighted associa-
tions between somatic mutations and non-malignant dis-
ease.7,8 Somatic STAT3 mutations occur in diseases with
autoimmune manifestations, such as large granular lym-
phocyte (LGL) leukemia and aplastic anemia.9-12 In LGL
leukemia, patients present with immune-mediated
cytopenias and rheumatoid arthritis, and LGL leukemia
patients with multiple STAT3 mutations more often have
RA (46%) than patients without mutations (6%).13
Somatic, activating STAT3 mutations have also been dis-
covered in intraepithelial lymphocytes of refractory celiac
disease patients14 and in patients with Felty syndrome
(long-lasting RA and neutropenia).15 Recent reports by us
and others have shown that somatic mutations in genes
other than STAT3 occur in mature T cells.16,17 For example,
patients with untreated RA have somatic mutations in
mature CD8+ T cells in 20% of cases.16
In addition to mutations in mature T cells, hematopoi-
etic progenitor cells may also harbor mutations: somatic
mutations originating from hematopoietic progenitor cells
occur in 10% of elderly individuals, and these mutations
confer a risk for blood cancer and cardiovascular disease.18-
20 These stem-cell-derived mutations have effects beyond
malignant transformation. For example, somatic loss-of-
function Tet2mutations in myeloid cells lead to proinflam-
matory cytokine production and increased atherosclerosis
in mice.21 As another example, somatic mutations in the
FAS gene in hematopoietic precursors can lead to autoim-
mune lymphoproliferative syndrome (ALPS).22
Thus, somatic events in blood cells have the potential to
modulate immune-mediated diseases. To study whether
patients with late-onset CVID and other immunodeficien-
cy and/or severe autoimmunity have somatic mutations in
CD4+ and CD8+ cells, and whether they associate with
disease phenotype, we used a customized deep sequenc-
ing panel covering 2,533 genes. In addition, to characterize
the CD4+and CD8+ T-cell repertoire in more detail, we
investigated the T-cell clone size, clonality, and character-
istics by deep T-cell receptor b-chain (TCRB) sequencing.
Methods
Patients
We recruited eight patients with late-onset CVID and nine
patients with other types of immunodeficiency or severe
autoimmunity from the Helsinki University Hospital infectious
disease clinic (Table 1). CVID patients were included in a previ-
ously described CVID cohort.3 Five of the patient cases with
other types of immune deficiency or severe autoimmunity have
been previously described: patient 17 has a germline mutation in
ADA2 (p.Arg169Gln/p.Arg169Gln) and somatic STAT3 D661V
and N647I mutations in T cells;23 patients 9-11 have germline
gain-of-function mutations in STAT3;24 and patient 12 has a
compound immunodeficiency and arr11q24.2q25 (126,074,297-
134,927,114) x 1 (Jacobsen syndrome).25 Blood donor buffy coat
samples from the Red Cross Blood Service (Online Supplementary
Table S1) served as healthy controls. This study was approved
by the local ethics committee and was conducted according to
the principles of the Declaration of Helsinki. All patients signed
informed consent. 
Sample preparation
CD4+ and CD8+ cells were purified via positive selection with
magnetic beads (Miltenyi Biotech) from peripheral blood
mononuclear cells. Sample material for patient 9 was bone mar-
row rather than peripheral blood. 
Identification of somatic mutations
To discover somatic variants, we designed a custom sequenc-
ing panel that comprised the coding areas of 2,533 genes. The
gene selection was based on the InnateDB database
(http://www.innatedb.ca/) and on other genes important for
hematopoietic cells, adaptive immune responses, and autoim-
munity (Online Supplementary Table S2). All samples (CD4+ and
CD8+ cells of 17 immunodeficiency patients and 21 healthy con-
trols) were sequenced with HiSeq2500 (Illumina). 
Somatic variants were identified with the GATK toolkit and
MuTect2 using a panel of 21 healthy controls (Online
Supplementary Methods). To discover variants occurring only in
CD4+ or CD8+ cells, variant calling was performed as a paired-
sample analysis, using CD4+ cells as a germline control and
CD8+ as a 'tumor' sample, and vice versa. In addition, we per-
formed variant calling without a germline control sample from
the same patient to discover variants that occur in both CD4+
and CD8+ cells. Variants identified by single-sample calling
method were required to occur in both CD4+ and CD8+ cells in
a known hematopoietic tumor suppressor or oncogene.18-20 All
variants were required to pass multiple quality filters (Online
Supplementary Methods). Only mutations that altered the amino-
acid coding sequence were reported, but non-coding mutations
were included in mutation signature analyses. Signaling path-
ways were annotated using the Reactome public database and
gene with Gene Ontology (GO) Consortium biological process
terms (Online Supplementary Table S3).
T-cell receptor b-chain sequencing 
T-cell receptor b-chain (TCRB) sequencing was performed
from CD8+ and CD4+ cells’ genomic DNA with the human
TCRB immunoSEQ assay (Adaptive Biotechnologies) according
to the manufacturer’s instructions. The TCRB repertoires of
seven CVID patients and 27 healthy controls were compared.
Only productive T-cell receptor (TCR) sequences were analyzed.
To search for public, previously reported TCR sequences associ-
ated with pathogens, autoimmunity, or cancer, we queried TCR
against the manually curated McPAS database. “Convergent
TCR” were defined as clones that share an amino-acid CDR3
sequence although they have distinct nucleotide CDR3
sequences. A T-cell clone was defined by a unique nucleotide
sequence (Online Supplementary Figure S1).
Data sharing
Original sequencing data are available from the corresponding
author upon reasonable request due to ethical permit con-
straints.
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Table 1. Patient phenotypes.
ID             Germline                 Disease          Age at       Age at       Sex                           Phenotype                                                            Details
                  variant?                                      sampling        dg                                                                                                                             
1                      No                          CVID                61               59             M                Infections, autoimmunity,            Atrophic gastritis, colitis, GLILD, bronchiectasis, 
                                                                                                                                  enteropathy, lymphoproliferation     liver cirrhosis, splenomegaly,  lymphadenopathy
2                      No                          CVID                67               65             M                Infections, autoimmunity,                                 ITP, GLILD, splenomegaly, 
                                                                                                                                          granulomatous disease,                                          lymphadenopathy
                                                                                                                                               lymphoroliferation                                                                
3           TACI S68fsX11               CVID                54               42             M                Infections, autoimmunity,                                   GLILD, bronchiectasis, 
                                                                                                                                          granulomatous disease,                                  cholestasis due to hepatic
                                                                                                                                              lymphoproliferation                               LGL infiltration, chronic gastritis,
                                                                                                                                                                                                               sicca, psoriasis, portal hypertension, 
                                                                                                                                                                                                        LGL lymphoproliferation, thrombocytopenia, 
                                                                                                                                                                                                                    splenomegaly, lymphadenopathy
4           No exome seq               CVID                70               59             M                Infections, autoimmunity                  Hyperthyroidism, asthma, chronic gastritis
5                      No                          CVID                70               68             F                 Infections, autoimmunity,                               Atrophic gastritis, psoriasis,
                                                                                                                                              lymphoproliferation                                         asthma, splenomegaly
6           No exome seq               CVID                67               64             F                 infections, autoimmunity                   Hypothyroidism, vitamin D malabsorption
7                     No                          CVID                35               32             F                 Infections, autoimmunity,                             Neutropenia, anterior uveitis,
                                                                                                                                          granulomatous disease,                                              sicca, GLILD, 
                                                                                                                                              lymphoproliferation                                              lymphadenopathy 
8                      No                          CVID                37               30             M                Infections, autoimmunity,                                ITP, AIHA, hyperthyroidism, 
                                                                                                                                          granulomatous disease,                          sialadenitis, GLILD, splenomegaly, 
                                                                                                                                              lymphoproliferation                                              lymphadenopathy
9            STAT3 K658N           STAT3 GOF          17               17             F               Autoimmunity, enteropathy,                               Autoimmune enteropathy, 
                                                                                                                                    lymphoproliferation, infections                  bronchiectasis, asthma, cryptogenic 
                                                                                                                                                                                                                  organizing pneumonia, dermatitis,
                                                                                                                                                                                                             lymphadenopathy, splenomegaly, AIHA, 
                                                                                                                                                                                                        sicca, uveitis, sterile pleuritis, short stature, 
                                                                                                                                                                                                                         bone-marrow eosinophilia,
                                                                                                                                                                                                                           hypogammaglobulinemia
10          STAT3 K392R           STAT3 GOF          15               15             F                 Autoimmunity, infections,                         Neonatal diabetes, celiac disease, 
                                                                                                                                              lymphoproliferation                     rudimentary pancreas,  T-cell LGL leukemia, 
                                                                                                                                                                                                              desquamative interstitial pneumonitis,
                                                                                                                                                                                                     AIHA, bone-marrow eosinophilia, severe allergy, 
                                                                                                                                                                                                             short stature, hypogammaglobulinemia
11          STAT3M394T           STAT3 GOF          22               22             F                           Autoimmunity,                                              ITP, lymphocytic colitis, 
                                                                                                                                             lymphoproliferation,                               splenomegaly, lymphadenopathy, 
                                                                                                                                                       infections                                                 hypogammaglobulinemia
12        No exome seq,       Jacobsen sdr         46               45             F                              Infections,                                       ITP, neutropenia, hypothyroidism,
              arr11q24.2q25                                                                                                           autoimmunity,                                    condylomas, angioedema, asthma, 
               (126,074,297-                                                                                                       lymphoproliferation                                splenomegaly, lymphadenopathy, 
            134,927,114) x 1                                                                                                                                                                                 hypogammaglobulinemia
13                   No                         Other               73               67             F                                                                              Hypogammaglobulinemia, recurrent stomatitis
14                   No                         Other               70              NA             F                 Infections, autoimmunity                       Recurrent EBV meningoencephalitis, 
                                                                                                                                                                                                                  palindromic seronegative arthritis
15                   No                         Other               60               55            M                          Autoimmnunity                          Periorbital adul-onset xantogranulomatosis, 
                                                                                                                                                                                                                psoriatic arthritis, ulcerative colitis, 
                                                                                                                                                                                                                           asthma, alopecia, stroke 
16         No exome seq           Good sdr            70               59             M                Infections, autoimmunity                   LGL lymphoproliferation, bronchiectasis, 
                                                                                                                                                                                                                     sicca, seronegative rheumatoid 
                                                                                                                                                                                                     arthritis/tenosynovitis, hypogammaglobulinemia
17    ADA2 R169Q/R169Q       ADA2 def            41               41             F                 Infections, autoimmunity,                                   ITP, AIHA, neutropenia, 
                                                                                                                                              lymphoproliferation               LGL lymphoproliferation, hypogammaglobulinemia, 
                                                                                                                                                                                                             pulmonary hypertension, splenomegaly
Phenotypes of the patients included in the study. Eight were late-onset common variable immunodeficiency (CVID) patients, other patients had another type of immunodefi-
ciency or severe autoimmunity. The column “Germline variant” shows the results of clinical exome sequencing: if a pathogenic variant was identified, it is shown. ID: identifier;
dg: diagnosis; M: male; F: female; ITP: immune thrombocytopenic purpura; GLILD: granulomatous-lymphocytic interstitial lung disease; LGL: large granular lymphocyte; AIHA:




All patients but one included in the study had autoim-
mune disease manifestations, and 11 of 17 (65%) had lym-
phoproliferation (Table 1). All CVID patients (patients 1-8)
suffered from recurrent infections. Lymphoproliferation,
as defined by lymphadenopathy and/or splenomegaly,
occurred in 75% of CVID patients, granulomatous disease
in 12.5%, and enteropathy in 12.5%. Because we included
only late-onset CVID in the study, the median age at diag-
nosis was 59 years for CVID patients. 
According to the EUROClass classification system, 25%
(2 of 8) of CVID patients did not have B cells (B-) (Online
Supplementary Table S4). In the remaining B+ patients,
switched memory-B cells (CD19+CD27+IgDnegIgMneg) were
low in 50% (3 of 6) of cases. None had high frequencies of
transitional B cells (CD19+CD38++IgM++), and 67% (4 of 6)
had increased CD21low cells (CD19+CD21lowCD38low)
according to the EUROClass system. Other patients were
similarly classified, although they did not have CVID
(Online Supplementary Table S4).
Somatic mutations in CD4+ and CD8+ cells
The custom gene panel covered the coding areas of
2,533 genes, spanning over approximately 5.2 million
base-pairs. Immunodeficiency patients harbored 45 and
healthy controls 28 somatic mutations that existed in
either CD4+ or CD8+ cells, identified by paired-sample
variant calling (Table 2, Figure 1 and Online Supplementary
Table S5). In two cases, we had access to non-hematopoi-
etic-tissue-derived DNA; the mutations did not exist in
these samples (Online Supplementary Table S6). The preva-
lence of somatic mutations was 65% (11 of 17) in immun-
odeficiency patients, 75% (6 of 8) in CVID, and 48% (10
of 21) in healthy controls. The median ages of patients
and controls were similar (Figure 2A and Online
Supplementary Table S1). There was no statistically signif-
icant difference in the prevalence of mutations between
patients and controls (Figure 2B) or in the number of iden-
tified mutations (Online Supplementary Figure S2). The
median number of mapped bases was higher in immun-
odeficiency samples, but the number of mutations did
not correlate with mapped bases in CD8+ cells, in which
most mutations were discovered (Online Supplementary
P. Savola et al.
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Table 2. Selected somatic mutations identified in CD4+ and CD8+ cells.
Pt. ID    Disease         Cells              HGVS                                    AA change                         COSMIC identifier      Gene         VAF      SIFT    Polyphen2   ExAC All
1                CVID              CD8+        1:g.1804503C>G         NM_001282539:exon6:c.G346C:p.G116R                                             GNB1           0.07          D                D                 NA
2                CVID              CD4+      4:g.105235713delC    NM_001127208:exon3:c.1771delC:p.Q591fs                                           TET2           0.056        NA              NA                NA
                                         CD4+      4:g.105243618G>T      NM_001127208:exon6:c.G3643T:p.E1215X       COSM3719016           TET2           0.053        NA              NA                NA
                                         CD4+      16:g.50699619G>T            NM_022162:exon2c.G205T:p.E69X                                                  NOD2           0.06         NA              NA                NA
                                         CD4+      4:g.105269703C>T      NM_001127208:exon9:c.C4138T:p.H1380Y         COSM87161             TET2           0.027         D                D            0.000092
                                         CD4+      17:g.42217380A>T         NM_012448:exon10:c.T1254A:p.N418K                                             STAT5B         0.036         D                D                 NA
3                CVID              CD8+      7:g.100677602C>G          NM_005273:exon6:c.C372G:p.Y124X                                                 GNB2          0.051        NA              NA                NA
                                         CD8+      11:g.75290010T>G             NM_004041:exon2:c.A50C:p.K17T                                                  ARRB1         0.025         D                D                 NA
4                CVID              CD4+        9:g.5073770G>T        NM_001322195:exon13:c.G1849T:p.V617F         COSM12600             JAK2           0.017         D                D              0.0007
12      Jacobsen sdr      CD4+      22:g.36929726C>T          NM_000395:exon6:c.C637T:p.R213W                                              CSF2RB        0.026         D                D                 NA
                                         CD4+      19:g.47319962C>T            NM_001736:exon2:c.C185T:p.T62M              COSM400357           C5AR1           0.02          T                 D            0.000049
                                         CD8+       X:g.21432736G>A           NM_014927:exon3:c.G353A:p.R118Q                                              CNKSR2         0.03          T                 D                 NA
13             Other             CD4+      17:g.42210194G>C        NM_012448:exon15:c.C1883G:p.T628S          COSM6022929         STAT5B         0.032         D                D            0.000015
15             Other             CD8+      22:g.25667739C>G          NM_005160:exon6:c.C442G:p.P148A                                                 GRK3          0.034         P                 P                 NA
16          Good sdr          CD8+       1:g.56692436C>T            NM_006252:exon4:c.C409T:p.H137Y                                               PRKAA2        0.032         D                D                 NA
                                         CD8+      12:g.25227351G>A             NM_004985:exon3:c.C173T:p.T58I               COSM87288,             KRAS           0.079         D                D                 NA
                                                                                                                                                                                COSM5490513
                                         CD8+      19:g.47320366C>T          NM_001736:exon2:c.C589T:p.R197W           COSM4667798          C5AR1           0.13          T                 P            0.000033
17          ADA2 def          CD8+      5:g.138466921G>A           NM_001964:exon2:c.G472A:p.V158I                                                 EGR1          0.023         D                 P                 NA
HC1        Healthy           CD8+       9:g.35707732T>C        NM_006289:exon35:c.A4631G:p.K1544R                                              TLN1          0.021         T                 P                 NA
HC3        Healthy           CD8+      15:g.41056702G>A         NM_017553:exon17:c.C1990T:p.R664C         COSM5383245,          INO80          0.068         D                D                 NA
                                                                                                                                                                                  COSM5383244                
HC11      Healthy           CD8+       2:g.25240306A>G          NM_175629:exon19:c.T2318C:p.L773P          COSM1583115        DNMT3A       0.043         D                D                 NA
                                         CD8+      9:g.130880097T>C          NM_007313:exon9:c.T1510C:p.S504P                                                 ABL1           0.059         D                 P                 NA
HC16      Healthy           CD8+      3:g.184365148T>G        NM_001278698:exon3:c.T173G:p.L58W                                            POLR2H        0.032         D                D                 NA
                                         CD8+       4:g.38797118T>C          NM_003263:exon4:c.A1714G:p.M572V                                                TLR1           0.021         T                 B                 NA
HC17      Healthy           CD8+      5:g.148827319T>G          NM_000024:exon1:c.T488G:p.L163R                                               ADRB2         0.057         D                D                 NA
                                         CD8+      15:g.74036026C>G         NM_033247:exon5:c.C1274G:p.A425G                                                PML           0.025         T                 B                 NA
                                         CD8+      16:g.31266064A>T        NM_001145808:exon5:c.A344T:p.E115V                                             ITGAM          0.05          D                 P                 NA
                                         CD8+      21:g.31251838C>G         NM_003253:exon6:c.G1315C:p.A439P                                               TIAM1         0.029         T                 D                 NA
                                         CD8+      21:g.31266560T>A           NM_003253:exon5:c.A413T:p.D138V                                                TIAM1         0.047         D                 P                 NA
HC20      Healthy           CD8+     11:g.129870009T>C       NM_006165:exon22:c.A3091G:p.I1031V                                             NFRKB         0.054         T                 P                 NA
HC21      Healthy           CD4+      1:g.114716123C>T            NM_002524:exon2:c.G38A:p.G13D                 COSM573               NRAS          0.018         D                 B           0.0000082
Selected mutations identified in healthy controls and immunodeficiency patients in CD4+ and CD8+ cells. The mutations were identified in paired-sample analyses in either CD4+ or CD8+
cells. Patient (Pt.) 17 had also somatic STAT3 mutations in T cells (D661V and N647I), but they did not pass all MuTect2 filters due to clustered events and are thus not listed in the table.
CVID: common variable immunodeficiency; ID: identifier; AA: amino acid; VAF: variant allele frequency; SIFT: SIFT prediction; PolyPhen2: Polyphen2 HDIV prediction; T: tolerated; D: dele-
terious (SIFT)/probably damaging (PolyPhen2); B: benign; P: possibly damaging; ExAC all: the variant frequency in the general Exome Aggregation Consortium; sdr: syndrome; def: defi-
ciency; COSMIC: Catalogue of Somatic Mutations in Cancer.
Table S7 and Online Supplementary Figure S3). The vertical
and horizontal coverage of the assay is shown in Online
Supplementary Figure S4.
In immunodeficiency patients, the identified mutations
comprised of 38 missense, 5 nonsense, and 2 frameshift
mutations (Figure 2C). Immunodeficiency patients har-
bored a larger proportion of damaging mutations than
healthy controls (56% vs. 21%, Fisher’s exact test
P=0.0069) (Figure 2D). For CVID patients, the proportion
of damaging mutations was even higher (70%; P=0.0007
when compared with healthy controls). Damaging muta-
tions were defined as frameshift, nonsense and as muta-
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Figure 1. Discovered somatic mutations in CD4+ and CD8+ cells in patients and controls. Selected somatic mutations in patients and healthy controls identified in
paired-sample variant calling analyses are shown, with different colors representing different mutation types (missense, nonsense, frameshift, splicing; see color
code). Mutations were grouped according to Reactome pathways, but one gene was grouped only to one pathway for visual clarity. For immunodeficiency patients,
the patient phenotypes are also shown at the top of the figure. Patients 1-8 had common variable immunodeficiency (CVID). Oncogenes and tumor suppressors rel-
evant for hematopoietic tissue were derived from previous publications.18-20 The mean RNA expression of the mutated genes in healthy individuals' CD4+ (n=3) and
CD8+ (n=5) is shown as log2-transformed counts per million (cpm) values, and error bars represent standard deviation. B2M and ACTB are shown as highly-expressed
housekeeping gene references for expression levels. HC: healthy control; ACTB: actin beta; B2M: beta-2-microglobulin; cpm: counts per million.
tions with damaging predictions by both Polyphen-2 and
SIFT. Mutations in known tumor suppressors or onco-
genes18–20 occurred in six patients (35%) and two controls
(9.5%) (Figure 1). Gene Ontology (GO) term annotations
revealed that patients harbored variants in genes that
associate with lymphocyte functions (5 patients, 29%),
inflammation (7 patients, 41%), and proliferation (8
patients, 47%).  Most genes that harbored mutations
were expressed in healthy CD4+ and CD8+ cells (Figure 1),
suggesting functional relevance. Mutational signature
analysis revealed that the most dominant signature in
immunodeficiency patients’ CD4+ and CD8+ cells was
age-related signature 1. Mismatch-repair-associated sig-
nature 15 was more dominant in healthy controls’ CD4+
cells (Figure 2E).
Clonal hematopoiesis variants in CD4+ and CD8+ cells
To complement the findings in paired-sample analyses
by discovering variants that occur in both CD4+ and
CD8+ cells, we performed single-sample variant calling
analysis in genes associated with clonal hematopoiesis.18-
20 In the immunodeficiency cohort, 24% of patients (4 of
17) had in total seven clonal hematopoiesis-associated
variants while none was observed in healthy controls
(Table 3 and Figure 1). Patients who had clonal
hematopoiesis variants harbored more mutations in
CD4+ cells than patients without clonal hematopoiesis
(Figure 2F). Deep sequencing from flow cytometry-sort-
ed cells assessed the cellular lineage of these variants.
Clonal hematopoiesis-associated variants were found in
sorted, pure CD3+ T cells, and, in some cases, in CD19+
P. Savola et al.
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Figure 2. The prevalence and consequences of somatic muta-
tions in immunodeficiency patients and healthy controls. (A)
There was no statistically significant difference (Mann-Whitney
test) in median age (years) between immunodeficiency
patients and healthy controls. (B) The prevalence of somatic
mutations in CD8+ cells, CD4+ cells, and in either CD4+ or CD8+
(overall) in patients and controls. (C) The percentages of differ-
ent mutation types in immunodeficiency patients and healthy
controls (see color code). (D) Immunodeficiency patients har-
bored a larger proportion of damaging mutations than healthy
controls (Fisher exact test, P=0.0069). Damaging mutations
were defined by being either a nonsense, frameshift, or mis-
sense mutations with damaging predictions by both
PolyPhen2 and SIFT. (E) Mutational signatures in healthy con-
trols’ and immunodeficiency patients’ CD4+ and CD8+ cells.
Both non-coding and protein-altering mutations were included
in the analyses. Signatures with significant weights (>0.06)
are shown; others are classified as “Other”. (F) The number of
mutations in paired analyses in CD4+ and CD8+ cells were
compared between immunodeficiency patients who harbored
clonal hematopoiesis variants in both CD4+ and CD8+ cells.
The clonal hematopoiesis variants themselves were not
included in the analyses, but their existence was used as a
grouping factor. Patients with clonal hematopoiesis variants in
both CD4+ and CD8+ cells (clonal hematopoiesis) harbored
more somatic mutations in CD4+ cells than patients without
clonal hematopoiesis variants (Mann-Whitney test,
P=0.03439), but there was no statistically significant differ-





B cells. There were no mutations in CD14+ monocytes
(Online Supplementary Table S8).
Somatic mutations in key immunologic pathways
Overall, mutations occurred in genes that are linked
with cell proliferation and hematologic malignancies.
Patient 2 harbored the highest number of mutations:
seven in CD4+ cells and two in CD8+ cells. This patient
had a STAT5B (N418K) mutation in CD4+ cells with 3.3%
variant allele frequency (VAF), but also a NOD2 and four
different TET2 mutations in CD4+ cells (Tables 2 and 3,
and Figure 1). The patient had late-onset CVID with mul-
tiple co-morbidities: infections, idiopathic thrombocy-
topenic purpura (ITP), granulomatous-lymphocytic inter-
stitial lung disease (GLILD), splenomegaly, lym-
phadenopathy, and granulomas (Table 1). 
Patient 13 also harbored a STAT5B T628S mutation
with 3.2% variant allele frequency (VAF) in CD4+ cells
(Table 2 and Figure 1). In addition, she had a truncating
clonal hematopoiesis-associated DNMT3A variant in
both CD4+ and CD8+ cells (Table 3). Her disease pheno-
type comprised of hypogammaglobulinemia and recur-
rent, non-infectious stomatitis. Patient 16 harbored seven
mutations in CD8+ cells and one in CD4+ cells, occurring
in genes involved in RAF/MAPK and GPCR signaling,
TP53 regulation and inflammasome activity (KRAS T58I,
C5AR1, PRKAA2 and MEFV) (Figure 1). In addition, this
patient had two clonal hematopoiesis-associated variants
in both CD4+ and CD8+ cells (Table 3). This patient's
immunodeficiency presented as Good syndrome with
LGL lymphoproliferation, bronchiectasis, sicca, seronega-
tive RA/tenosynovitis, hypogammaglobulinemia, and
infections (Table 1). 
Patient 12 harbored five mutations in CD4+ cells and
three in CD8+ cells. Mutations included a C5AR1 muta-
tion, and two mutations in RAF/MAPK signaling cascade
genes (CNKSR2 and CSF2RB) (Table 2 and Figure 1). The
patient had Jacobsen syndrome with infections,
hypogammaglobulinemia, lymphoproliferation, and mul-
tiple autoimmune manifestations (Table 1).
To validate a subset of mutation findings, we per-
formed Amplicon re-sequencing of interesting mutations
(23 different positions in patients) and negative control
positions (Online Supplementary Methods and Online
Supplementary Table S9) with a multiplexed customized
amplicon panel. All mutation positions covered by suffi-
cient coverage (20 of 23, 87%) were successfully validat-
ed (20 of 20, 100%). As expected, mutations were only
detected in the original patient and not in other individu-
als. All control positions yielded negative results.
Mutations presented with similar VAF in re-sequencing as
in the original sequencing assay (Online Supplementary
Table S10). 
CD4+ clonality correlates with CD8+ clonality and 
B-cell phenotypes
There was no difference in clonality indices of either
CD4+ or CD8+ cells between patients and controls (Figure
3A). Overall, CD8+ cells showed higher clonality than
CD4+ cells (P<0.0001 in healthy controls; P=0.0135 in
CVID) (Figure 3A). The size of the largest T-cell clone (as
frequency of all productive rearrangements) and the pro-
portion of productive sequences of all TCRB rearrange-
ments were similar in patients and controls (Online
Supplementary Figure S5).
CD4+ and CD8+ clonality showed a positive non-linear
correlation in both CVID and healthy controls (Figure 3B;
Spearman correlation P=0.0019 and P=0.0234, respective-
ly). An increased proportion of CD8+ cells was associated
with higher clonality in CD4+ and CD8+ cells (Figure 3C;
Spearman correlation P=0.0238 CD4+ clonality and
0.0341 CD8+ clonality). The largest T-cell clone size was
greater in individuals with mutations than in individuals
without mutations (Online Supplementary Figure S6). Due
to the importance of helper T cells in B-cell maturation,
we correlated CD4+ clonality indices with the frequencies
of different B-cell subsets in CVID patients. Higher CD4+
clonality correlated with lower frequencies of memory
and switched memory B cells (P=0.008 and P=0.0238)
(Figure 3D and E). CD4+ clonality did not associate with
the frequency of total B cells, marginal-zone, activated, or
transitional B cells (Online Supplementary Figure S7).
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Table 3. Clonal hematopoiesis variants occurring in both CD4+ and CD8+ cells.
Pt. ID                                                    AA change                                                   Consequence        COSMIC identifier          Cell type           VAF
13                        DNMT3A:NM_022552:exon20:c.2388dupT:p.N797_L798delinsX                    Nonsense                                                               CD4+                0.043
                                                                                                                                                                                                                                                   CD8+                0.038
2                                      TET2:NM_001127208:exon3:c.1771delC:p.Q591fs                               Frameshift                                                              CD4+                0.056
                                                                                                                                                                                                                                                   CD8+               0.0065
                                           TET2:NM_001127208:exon6:c.G3643T:p.E1215X                                  Nonsense                 COSM3719016                    CD4+                0.053
                                                                                                                                                                                                                                                   CD8+                0.027
                                         TET2:NM_001127208:exon11:c.C4889G:p.S1630X                                Nonsense                 COSM5945066                    CD4+                0.041
                                                                                                                                                                                                                                                   CD8+                0.032
17                                    DNMT3A: NM_022552:exon14:c.G1591A:p.D531N                                Missense                 COSM1583077                    CD4+                0.013
                                                                                                                                                                                                                                                   CD8+                0.024
16                                    DNMT3A: NM_022552:exon14:c.G1591A:p.D531N                                Missense                 COSM1583077                    CD4+                0.022
                                                                                                                                                                                                                                                   CD8+                0.027
                                           PRPF8:NM_006445:exon39:c.A6272G:p.Y2091C                                   Missense                                                               CD4+                0.019
                                                                                                                                                                                                                                                   CD8+                0.023
Variants that occurred in clonal hematopoiesis-associated genes and in both CD4+ and CD8+ cells in single-sample variant calling are shown. Pt. ID: patient identifier; VAF: variant
allele frequency; AA: amino acid; COSMIC: Catalogue of Somatic Mutations in Cancer.
T-cell receptor b-chain gene segment usage and 
junctional diversity
T-cell receptor b-chain V- and J-gene usage often serves
as a marker for structural similarity of TCR. In total pro-
ductive CD4+ and CD8+ TCR repertoires, there was no
difference in TCRB V-gene family and J-gene usage
between CVID patients and controls (Online
Supplementary Figure S8). When comparing junctional
diversity, no differences were found between patients and
controls in the sums of base deletions and non-templated
base insertions in the V-D and D-J junctions (Online
Supplementary Figure S9). All non-templated base edition
comparisons between CVID patients and controls are
shown in Online Supplementary Figure S10.
Common variable immunodeficiency patients harbor
higher frequencies of convergent T-cell receptor clones
than healthy controls
Distinct T-cell clones have unique nucleotide-level
CDR3 sequences, but different nucleotide sequences can
translate into the same functional CDR3 amino-acid
sequences (TCR convergence). CVID patients showed
more convergence in CD4+ and CD8+ cells than healthy
controls (CD4+ P=0.0123 and CD8+ P=0.0215) (Figure 3F).
This was not due to higher frequencies of previously
reported pathogen-specific TCR, such as Epstein-Barr
virus (EBV) or cytomegalovirus (CMV)-specific TCR, in
the CVID convergent TCR sequences (Online
Supplementary Figure S11). However, convergent clones did
not show higher abundance in CVID (abundance being
defined as the sum of all convergent clone rearrangement
frequencies) (Online Supplementary Figure S12).
We also investigated the physico-chemical properties of
highly convergent and highly expanded TCR sequences
with a generic string kernel algorithm (GSKernel) and
unsupervised clustering analyses: CD8+ cells had 275
expanded and 3,738 highly convergent clones, and CD4+
cells had 342 expanded clones and 848 highly convergent
clones. In CD8+ cells, these selected TCR formed 24 clus-
ters based on the TCR physico-chemical similarity (Figure
4A). Six clusters were enriched with CVID TCR (Figure
4B). A major determinant driving the clustering was J-gene
usage, but not V-gene usage (Online Supplementary Figure
S13). In CD4+ cells, selected TCR formed 20 clusters with
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Figure 3. T-cell repertoire characteristics in
common variable immunodeficiency (CVID)
patients. (A) Clonality indices of CD4- and
CD8-cell productive T-cell receptor (TCR)
rearrangements. No statistically significant
differences were seen between patients and
healthy controls, but CD8+ cells were more
clonal than CD4+ cells. Other: immunodefi-
ciency patients other than CVID. Statistical
testing comprised a Kruskall-Wallis test as
an omnibus test and Dunn multiple compar-
ison tests as post-hoc tests. Medians and
interquartile ranges are shown. (B) CD4+
and CD8+ clonality indices correlate with
each other, but not in a linear fashion. (C)
Low CD4/CD8 ratios are associated with
higher CD8 clonality. (D) Increased CD4+
clonality is associated with decreased fre-
quency of memory B cells in CVID patients
(Spearman correlation, P=0.0008). (E)
Increased CD4+ clonality is associated with
decreased frequency of switched memory B
cells in CVID patients (P=0.0238). (F) CVID
patients show a higher frequency of conver-
gent TCR of all TCR amino-acid rearrange-
ments (Mann-Whitney test, P=0.013 for
CD4+ and P=0.021for CD8+ ). Vertical lines:
median; box hinges: interquartile ranges;
whiskers: reasonable extremes of the data;
ns: not significant; HC: healthy control; CVID:
common variable immunodeficiency; Other:
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similar results (Figure 4C and Online Supplementary Figure
S14). Interestingly, convergent CD8+ TCR in CVID had
slightly different properties when compared to control
TCR: CVID TCR showed a difference in polarity and
hydrophobicity when compared to controls (Online
Supplementary Table S11), whereas no differences were
seen in CD4+ TCR.
CD8+ cells show higher frequencies of antigen-specific
T cells than CD4+ cells
Lastly, we investigated whether CVID patients had
higher frequencies or abundances of previously reported
TCR, with a focus on pathogen-specific TCR (see
“Methods” section). There was no difference in frequencies
of antigen-specific TCR between CVID patients and con-
trols (Online Supplementary Figures S15 and S16; healthy
CD4+ vs. CVID CD4+, and healthy CD8+ vs. CVID CD8+).
However, in healthy controls, the frequencies of
pathogen-specific, cancer-specific, and autoimmune-asso-
ciated TCR were higher in CD8+ cells than CD4+ cells, but
these differences were not statistically significant in CVID
(Online Supplementary Figures S15 and S16).  The abun-
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Figure 4. Convergent T-cell receptors (TCR) form structurally similar clusters, and some clusters enrich with common variable immunodeficiency (CVID) patients.
Convergent and highly expanded TCR were analyzed for physico-chemical structure similarity and visualized with t-distributed stochastic neighbor embedding (t-SNE).
Only highly convergent TCR and large clones (defined in “Methods”) were included in the analyses. Each dot represents a single TCR, and each TCR can be mapped
to one patient. (A) Analyzed TCR formed 24 clusters in CD8+ cells, of which six were enriched with CVID TCR, as analyzed with Fisher's test (#). (B) The same clustering
analysis, with CD8+ CVID or healthy control (HC) TCR with colors. (C) Analyzed TCR formed 20 clusters in CD4+ cells, of which two were enriched with CVID TCR (#).
(D) The same clustering analysis, with CD4+ CVID or HC TCR with colors. 
A B
C D
dance of pathogen-specific, but not cancer or autoimmune
TCR, was also increased in CD8+ when compared to
CD4+ cells in controls.
T-cell clone size and somatic mutation variant allele
frequency
Individuals with mutations had larger CD8+ T-cell
clones, but similar association was not observed among
CD4+ T cells (Online Supplementary Figure S6). We plotted
the frequency of the largest T-cell clone and mutation VAF
(Online Supplementary Figure S17) to investigate the rela-
tionship between the clone size and VAF.  If a somatic
mutation occurs only in one individual T-cell clone, the
mutation VAF should be half the clone size or less (assum-
ing that most somatic mutations are heterozygous). In
CD8+ T cells this was true, and mutation VAF correlated
well with the clone size (Online Supplementary Figure S17).
However, in some cases, the mutation VAF in CD4+ cells
were higher than expected (Online Supplementary Table S12
and Online Supplementary Figure S17), suggesting that
mutations occur also in other cells rather than just in one
CD4+ T-cell clone. Using flow cytometry-mediated sorting
and sequencing, we confirmed that the mutations were
still confined to the CD4+ T-cell fraction as they did not
occur in other cell types, such as CD14+ cells or CD3+CD8+
cells (patients with STAT5B mutations) (Online
Supplementary Table S13). However, clonal hematopoiesis-
associated variants occurred in both CD4+ and CD8+ cells
(Table 3 and Online Supplementary Table S8).
Discussion
In our small cohort (n=17) of late-onset CVID and other
immunodeficiency patients, we show that somatic muta-
tions occur in CD4+ and CD8+ cells in 75% of the CVID
patients and in 65% of all patients. Lymphoproliferation
(65%) and autoimmune disease manifestations were high-
ly prevalent (94%) in our study cohort. Healthy controls
harbored mutations in 45% of cases. Considering also the
data on somatic mutations occurring in either CD4+ or
CD8+ cells, we identified clonal hematopoiesis variants in
both CD4+ and CD8+ cells in 24% of immunodeficiency
patients. CVID patients also harbored higher frequencies
of convergent TCR than healthy controls, and clustering
analyses on selected TCR identified structurally similar
TCR clusters that were enriched with CVID TCR.
Somatic mutations occur throughout life at an estimated
rate of 3.5*10-9–1.6*10-7 per base-pair per mitosis in many
somatic tissues.26 Since somatic mutations accumulate
with age, the discovery of somatic mutations in CD8+ and
CD4+ cells is not unexpected.27-29 The majority of the iden-
tified mutations occurred in CD8+ cells, which could be
due to the higher clonality of CD8+ T cells. In agreement
with this, our results showed that patients with mutations
had larger CD8+ T-cell clones. However, it should be noted
that although the overall CD4+ clonality was low, many
immunodeficiency patients harbored mutations also in
CD4+ cells. Interestingly, the most dominant mutational
signatures in T cells were signatures 1 and 15. Signature 1
correlates with age and derives from spontaneous deami-
nation of 5-methylcytosine;30 this signature was especially
dominant in CD8+ cells and in immunodeficiency patients.
Signature 15, which associates with  defective mismatch
repair,31 was more prominent in healthy control CD4+ cells.
Many of the genes with somatic mutations in immun-
odeficiency patients link to malignant disorders, autoim-
munity, or lymphoproliferative disorders. Somatic muta-
tions in known hematologic tumor suppressors and/or
oncogenes18-20 occurred in 35% of immunodeficiency
patients. CVID patients harbored these mutations in 38%
(3 of 8) of cases and healthy controls in 9.5% (2 of 21).
Two patients harbored somatic STAT5B mutations
(patient 2, N418K; patient 13, T628S) in CD4+ cells. The
T628S mutation in patient 13 results in increased STAT5
phosphorylation, transcriptional activity, and cell prolifer-
ation.32 Activating STAT5B mutations in lymphocytes
occur especially in CD4+ T-cell large-granular lymphocyte
leukemia and T-prolymphocytic leukemia.32,33 Patient 16
harbored a KRAS T58I mutation in CD8+ cells with VAF
7.9%. KRAS is mutated in nearly 30% of cancers,34 and
somatic activating KRASmutations in both lymphoid and
myeloid cells are observed in Ras-associated autoimmune
leukoproliferative disorder.35 Of note, the patient had a
major T-cell clone in CD8+ cells comprising 51% of all
CD8+ cells. Two patients had C5AR1 (complement C5a
receptor 1) mutations. Recent data indicate that C5AR1
activation promotes the proinflammatory Th1 responses
in CD4+ cells via reactive oxygen species and inflamma-
some activation.36
Due to the lack of statistical power and differences in
sequencing coverage, we cannot draw conclusions about
the differences in mutation prevalence and mutation
counts between immunodeficiency patients and controls.
Although immunodeficiency patients had potentially
pathogenic variants, also healthy controls harbored muta-
tions in tumor suppressors and oncogenes, such as in
NRAS (G13D) and DNMT3A (L773P), which is not unex-
pected due to the high prevalence of clonal hematopoiesis
in 60-69 year olds.37-39 Nevertheless, immunodeficiency
patients had mutations that do not generally occur in
clonal hematopoiesis in the general population, such as
mutations in STAT5B. These mutations, or a subset of
them, could contribute to lymphoproliferation in these
patients, despite showing low VAF. Although the function
of the discovered mutations was not analyzed in our
study, previous studies by us and others suggest that
somatic mutations may alter the phenotype and function
of mutated T cells.16,40 Interestingly, Fraietta et al. has
shown that a hypomorphic TET2 mutation can lead to
the expansion and persistence of chimeric antigen recep-
tor (CAR)-T cells.40 Tet2 inactivation in mice results in
altered T- and B-cell differentiation, and TET2 mutations
occur in T-cell lymphomas.41 DNMT3A mutations may
also facilitate lymphoproliferation, as shown by Dnmt3a
deficiency leading to both myeloid and lymphoid malig-
nancies in mice.42 DNMT3A is also commonly mutated in
human acute 
T-cell lymphoblastic leukemias.42 The clinical relevance of
DNMT3A and TET2 mutations and the possible survival
advantage they may confer in immunodeficiency requires
more studies, as the prevalence of these mutations is rel-
atively high also in healthy T cells.
The majority of the detected mutations occurred exclu-
sively in CD4+ or CD8+ cells. The origin of these muta-
tions is elusive. Do these somatic mutations occur in one
T-cell clone or in multiple clones? Do they occur in every
cell of the same clone or only in a subset?  Any conclusive
answer could only be obtained through in-depth single-
cell sequencing studies. In our previous reports, we
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showed that mutations are confined to specific T-cell pop-
ulations in CD8+ cells.16 Similarly, in immunodeficiency
patient mutation, VAF and clone sizes matched well in
CD8+ T cells, suggesting that mutations occur late during
T-cell maturation. However, the analysis of CD4+ T cells
suggested that mutations may also occur in precursor
cells, as mutation VAF were higher than individual CD4+
T-cell clone sizes. 
In addition to mutations found exclusively in one cell
type, we also detected mutations which were found in
both CD4+ and CD8+ compartments, suggesting that they
could have originated from a hematopoietic stem cell, or
from multipotent or lineage-specific progenitors. Our
results are in line with previous publications showing that
clonal hematopoiesis-associated mutations (such as
DNMT3A and TET2) can occur in T cells.37,43,44 These muta-
tions likely originate from progenitor cells, because in our
cases they were found both in CD4+ and CD8+ T cells, and
in CD19+ B cells, but not in myeloid CD14+ cells.
However, myeloid cells can harbor the same mutations as
B cells (as in monoclonal B-cell lymphocytosis and indo-
lent chronic lymphocytic leukemia) or T cells (in individu-
als without hematologic disease).37,44-47 
In the present study, we detected somatic mutations
with relatively low VAF by using high sequencing cover-
age in the assays. To avoid exhaustion of the unique DNA
molecules, a sufficient amount of DNA (100-500 ng) was
used based on the calculations that one nanogram of DNA
comprises approximately 300 copies of unique DNA mol-
ecules. Assay sensitivity is also determined by other fac-
tors, such as sequencer performance and bioinformatics
approaches. In general, Illumina sequencers show a low
error rate,48 and we applied standard variant detection
practices with multiple quality filters (such as VAF thresh-
old and the requirement for at least seven supporting
reads for the variant), similar to reports by others using
capture sequencing technologies.7,18,19,49,50 
Although a previous study had suggested increased 
T-cell clonality in CVID patients,51 we did not observe any
difference in clonality between CVID and controls. The
heterogenous phenotypes of CVID patients, ages of con-
trols, and sample material may explain the difference in
results. Interestingly, however, we noted increased TCR
convergence in CVID. Previous studies have shown that
TCR convergence associates with clone size52 and public
TCR in mice.53 We hypothesize that convergence is due to
enrichment mediated by antigen stimulation. The latter is
further supported by the finding that CVID convergent
TCR showed some structural similarity (Figure 4), which
could be related to common antigen stimulation. 
In conclusion, we discovered somatic mutations and
increased TCR convergence in mature T cells in patients
with immunodeficiency. TCR convergence may be due
to a chronic antigen response, and somatic variants may
contribute to immune dysregulation. Somatic mutations
may originate either in mature T cells or hematopoietic
stem cells. Although healthy controls also harbor some
variants with potentially pathogenic consequences, our
results demonstrate that mutations in genes that have
been associated with autoimmunity and lymphoprolifer-
ation (such as STAT5B) occur in immunodeficiency
patients. Further studies are needed to discover the full
spectrum of somatic mutations and their role as possible
regulators of immune responses both in normal and dis-
eased T cells.
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